<DOC>
	<DOCNO>NCT00470457</DOCNO>
	<brief_summary>Allergen specific immunotherapy ( SIT ) causative treatment IgE-mediated allergy . The disadvantage SIT , however , requirement numerous allergen administration three five year , treatment cause frequent allergic reaction . We aim enhance grass pollen SIT hay fever patient inject allergen directly subcutaneous lymph node . In monocentric randomize trial safety efficacy intralymphatic immunotherapy ( ILIT ) 3 low dose grass pollen extract injection 2 month compare subcutaneous immunotherapy ( SCIT ) use 54 injection 3 year . - Trial immunodulatory product / biological</brief_summary>
	<brief_title>A Randomized Study Evaluate Novel Method Specific Allergen Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Inclusion criterion : Written inform consent History allergic rhinoconjunctivitis spring summer Age 18 year 65 year Positive skin prick test grass pollen Exclusion criterion : Blood donation within previous 30 day Surgery within previous 30 day Use investigational drug within previous 90 day Pregnancy nurse Mastocytosis Significant cardiovascular disease Hypertension Active infectious disease Significant hepatic disease Significant renal disease Significant hematological disorder Significant pulmonary disease Moderate severe asthma Autoimmune disease History malignancy . Contraindicated medication immunosuppressive agent , betablockers , ACEinhibitors , tricyclic antidepressant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>